Following research at Imperial College, we believe we’ve found a novel and effective treatment for relapsed/resistant cancer, targeting and killing cancer stem cells. With patents in place, we now need funding for the next phase: to complete lab-testing prior to clinical trials.
Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer.
If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations.
The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease.
Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy.
We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells.
We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature).
Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.